阿尔茨海默病综合多式细胞地图
Mariano I Gabitto1, Kyle J Travaglini1, Victoria M Rachleff1,2
1Allen Institute for Brain Science, Seattle, WA, 98109.
Research square
|June 9, 2023
概括
阿尔茨海默病 (AD) 的进展会影响特定的大脑细胞类型,观察到早期的神经元损失和晚期质变化. 这些细胞变化与认知衰退相关,为AD的分子机制提供了新的见解.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,其特点是蛋白质聚合物.
- 确切的AD进展和受影响细胞群的分子和细胞驱动因素尚未完全理解.
结论:
- 使用先进的多原子技术详细介绍了阿尔茨海默病进展的动态细胞格局.
- 揭示了在不同疾病阶段脆弱的特定神经元亚型.
- 建立了一个公共数据资源 (SEA-AD.org) 以促进进一步的阿尔茨海默病研究.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.2K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.2K
相关概念视频
01:26Alzheimer's Disease: Overview
536
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
536
01:22Alzheimer's Disease: Treatment
224
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
224